31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015)

• Record Type: Journal Article
• Authors: Toulmonde, M.; Le Tourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; De la Fouchardiere, C.; Flechon, A.; Desseigne, F.; Frappaz, D.; Gomez-Roca, C.A.; Heudel, P.E.; You, B.; Jaouen, L.; Bernardin, M.; Perol, D.; Blay, J.Y.
• Is Part Of: European journal of cancer. Volume 51:(2015)Supplement 3
• Page Start: S725
• Page End: S726
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)31949-9
• Languages: English
• ISSNs: 0959-8049